Листок дождя

[Intensity Therapeutics @IntensityInc]

Coordinating investigator @MarkusJoerger, MD, PhD Professor of Medicine at the University of Basel, shared his perspective on the potential of INT230-6 in the ongoing Phase 2 INVINCIBLE-4 study for patients with presurgical #TNBC.

Read more: https://t.co/hERqe8SGgN

$INTS

[Листок дождя @GastroManyak]

When a top manager leaves a stable CRO to join a biotech, it’s a huge signal. Amy Findling managed $INTS trials for 2.5 years. She knows the data from the inside. Joining the team now is the best confirmation of the drug's potential. 🚀

[Intensity Therapeutics @IntensityInc]

Please join us in welcoming Amy Findling to the $INTS team as Director of Project Management, Oncology!

After working alongside Intensity for the past 2.5 years, we're excited to officially have Amy join the team.

#NewHire

[Intensity Therapeutics @IntensityInc]

Speaking with @AsiaBioSpectrum at #BIO2026, $INTS' Founder and CEO, Lew Bender, discussed how intratumoral therapies may help turn tumors into personalized anti-cancer vaccines while reducing systemic toxicity.

Full interview: https://t.co/UvyKv3qNqQ

#BIOUS

[Листок дождя @GastroManyak]

@MS916003029686 @IntensityInc Why?

[Листок дождя @GastroManyak]

Huge milestone for $INTS. Being selected for a full presentation at #DiscoveryOnTarget proves that the scientific community is taking their intratumoral delivery platform very seriously. This kind of recognition isn’t handed out easily. Congrats to Lewis Bender & the team!

[Intensity Therapeutics @IntensityInc]

This fall, $INTS will participate in the Novel Modalities stream at @BostonDOT.

On Oct. 1 at 4:05 PM, #INTS Founder & CEO Lewis Bender will present on advances in intratumoral drug delivery and tumor uptake of anticancer agents.

Learn more: https://t.co/fQ8EOTBXPh

#BostonDOT

[Листок дождя @GastroManyak]

@JNJNews Look at INTS please

[Листок дождя @GastroManyak]

Widening the "strategic moat": $INTS gets a new U.S. patent and global coverage in 41 countries. A massive barrier for competitors. Signal to VC/Big Pharma: market leadership. 🚀
​#Biotech #VC #INTS #Oncology

[Intensity Therapeutics @IntensityInc]

$INTS strengthens its IP portfolio with a new U.S. patent (No. 12,496,345).

Patents now granted in 41 countries support its intratumoral technology, including #INT2306.

Full PR: https://t.co/r6hpqTxmmc

#Oncology

[Листок дождя @GastroManyak]

$INTS 71.4% pCR vs 33% SOC in TNBC Phase 2! 🧬 Fewer severe side effects (14 vs 25). Game-changer for oncology! 🚀
​@FierceBiotech @BioPharmaDive @Benzinga @StacyResbiotech @CarolineHydeTV @Stocktwits #INTS #Biotech #BreastCancer #Investing

[Intensity Therapeutics @IntensityInc]

. @cure_today features preliminary Phase 2 INVINCIBLE-4 data evaluating #INT2306 in triple-negative breast cancer.

Read more: https://t.co/1CKYEjgwuC

$INTS

[Листок дождя @GastroManyak]

Global IP is critical for oncology partnerships. 🛡️
​$INTS @IntensityInc now holds patents in 41 countries for its intratumoral tech, de-risking #INT230-6 worldwide. 🌍
​This validation should get the attention of @Merck @BMSnews @Pfizer.
​#Oncology #Partnering #BiotechLicensing

[Intensity Therapeutics @IntensityInc]

$INTS strengthens its IP portfolio with a new U.S. patent (No. 12,496,345).

Patents now granted in 41 countries support its intratumoral technology, including #INT2306.

Full PR: https://t.co/r6hpqTxmmc

#Oncology

[Листок дождя @GastroManyak]

@MS916003029686 @IntensityInc Why?

[Листок дождя @GastroManyak]

Incredible results for $INTS! 71.4% pCR vs 33% SOC in TNBC is a game changer. Safer and more effective – exactly what patients need. #BreastCancer #Biotech #Oncology
@Merck @AstraZeneca @BMSnews

[Intensity Therapeutics @IntensityInc]

$INTS Founder & CEO Lewis Bender shares his perspective on early observations from the Phase 2 INVINCIBLE-4 study evaluating INT230-6 in #TNBC.

Preliminary data showed 71.4% pCR and 44% fewer grade ≥3 adverse events vs SOC alone.

Read more: https://t.co/pFGqcz2J7X

[Intensity Therapeutics @IntensityInc]

$INTS Founder & CEO Lewis Bender shares his perspective on early observations from the Phase 2 INVINCIBLE-4 study evaluating INT230-6 in #TNBC.

Preliminary data showed 71.4% pCR and 44% fewer grade ≥3 adverse events vs SOC alone.

Read more: https://t.co/pFGqcz2J7X

[Intensity Therapeutics @IntensityInc]

$INTS provides an update on the Phase 2 INVINCIBLE-4 study in #TNBC.

Preliminary observations showed 71.4% pCR with INT230-6 prior to SOC vs 33% with SOC alone, and 44% fewer grade ≥3 adverse events.

Read more: https://t.co/pFGqcz2J7X

#ClinicalTrials

[Листок дождя @GastroManyak]

@MbarkCherguia Korochka

[Листок дождя @GastroManyak]

@SPANIELONSOL @IntensityInc Actually, clinical progress is a long-term catalyst, so the day doesn't matter. Plus, after the split, we need to attract institutional investors, and a Thursday PR could trigger a massive short squeeze before the weekend. Any day is a good day for INVINCIBLE-4 news dumb dumb

[Листок дождя @GastroManyak]

@IntensityInc As a shareholder, I’m concerned about the 1:25 split and future dilution. What is the plan to protect current investors? Also, will the CEO and management's stakes be diluted proportionally alongside us, or will they receive new grants to offset their loss?

[Intensity Therapeutics @IntensityInc]

#Breastcancer continues to impact hundreds of thousands, with @AmericanCancer estimating over 321,000 new invasive cases in the U.S. in 2026.

$INTS is advancing #INT2306 to activate the immune system and improve patient outcomes.

Learn more: https://t.co/5JI4ilF1x2

[Intensity Therapeutics @IntensityInc]

On a recent @pharmaphorum Podcast, Lew Bender, CEO of #IntensityTherapeutics, shared clinical observations from the INT230-6 Phase 1/2 trial, including encouraging outcomes in #sarcoma that supported the move into Phase 3.

Catch up on the full episode: https://t.co/DF5WaxK0hH

$INTS  #ClinicalTrials

[Intensity Therapeutics @IntensityInc]

$INTS' CEO, Lew Bender, joined @irat1onal on the Progress, Potential, and Possibilities podcast to discuss  #Intensity’s intratumoral approach and the science behind #INT2306.

Watch or listen to the full episode on @YouTube: https://t.co/WJMk0NOFhZ